Overview

Data to 2 Nov 2026
Back to site
Clinical status · data to 2 Nov 2026

Partial response on second-line treatment.

Metastatic melanoma, BRAF V600E, with disease in the liver and one lymph node. Encorafenib with binimetinib since 9 June 2026, after progression on ipilimumab and nivolumab. Tumour DNA, LDH and all measured lesions have fallen since June.

01Key measurements
02Tumour DNA in blood

Personalised tumour DNA

Mutant molecules per mL of plasma (MM/mL), log scale. Tumour-informed panel of 24 variants selected from whole-genome sequencing of the 2025 primary and the 2 Jun 2026 liver biopsy.

Liquid biopsy
Variants detected per drawTruncal, 17PTEN subclone, 4RAC1 subclone, 3Not detectedLimit of detection, 0.5 MM/mL

Resistance surveillance

Proposed criteria for an early CT before the scheduled scan. Any criterion met: CT chest, abdomen and pelvis within 2 weeks. Next blood draw 17 Nov 2026.

03Disease sites
Image monitoring
3-D model of the liver with two metastases, the liver veins, kidneys, spleen, aorta and spine

Liver, liver veins and the two lesions from the expert outlines of the CT of 8 Jan 2026; bones, kidneys, spleen and great vessels by automatic segmentation. The model loads after the rest of the page and pauses when scrolled out of view.

Sites

Contrast CT of 12 Oct 2026; volumes against the baseline CT of 8 Jan 2026.

04Lines of treatment
05Clinical course

Diagnosis in March 2025 to 2 Nov 2026. Each bar and marker has a tooltip with details.

06Molecular profile and safety

Molecular profile

Whole genome of the 2025 primary and the 2 Jun 2026 liver biopsy with matched blood; RNA of the liver biopsy.

Cancer cell fraction

Expression against 469 cutaneous melanomas, percentile

Safety status

Highest CTCAE grade of each side effect by month, 2026. Hover a cell for the detail.

NoneGrade 1Grade 2Grade 3
07Response assessment

Sum of target lesion diameters

RECIST 1.1 on five CT scans in 2026. Dashed lines: partial-response threshold, −30% against each line's baseline (68 mm for line 1, 58 mm for line 2).

Combined assessment · data to 2 Nov 2026

Partial response on second-line treatment: −39% by RECIST against the scan of 2 Jun 2026 (83 to 51 mm) and −79% by lesion volume. Tumour DNA 0.2%, LDH and S100B within their reference intervals.

Not assessed

08Plan

Next ten weeks

Scans, decisions, treatment cycles, blood tests and safety checks from 2 Nov 2026. Select a marker for the detail.

09Tumour board and trials

Decision map for the tumour board

Tumour board, 12 Nov 2026 13:00.

Trial eligibility

9 trials screened against the record. One dot per eligibility criterion; hover a dot for the criterion.

Trial matcher
MetNeeds a testTimingExcludes
10Record sections
11Treatment and response

Treatment and response

Initial response to ipilimumab with nivolumab was followed by progression. Tumour DNA, LDH and lesion volume have fallen since encorafenib with binimetinib started on 9 June.

Tumour DNA (%)LDH (U/L)

Changes last 30 days

    12Scheduled
    01Summary
    02Actionable findings

    Each finding is assessed against licensed treatments and published evidence. Levels follow ESCAT; I-A denotes benefit proven in randomised trials in this cancer. Levels are assigned only to findings linked to a treatment.

    03Mutations · single-letter changes and small insertions or deletions

    Position of each change in its protein. Grey stems: changes recorded in other melanomas in the reference set. Larger orange markers: changes in this tumour.

    Changes in cancer genes liver biopsy 2 Jun 2026, compared with the 2025 primary and blood

    Bars show the share of DNA reads carrying the change (VAF). Cancer-cell fraction is the share of cancer cells that carry it, after allowing for normal cells in the sample.

    04Copy number · gains and losses across the genome

    Copies of each part of the genome in the cancer cells, chromosomes 1 to 22. Two copies is normal. The lower line is the number of copies of the less common parent's chromosome; where it falls to zero, one parent's copy has been lost (loss of heterozygosity).

    GainLossTwo copiesMinor-parent copiesLoss of heterozygosity

    Treatment-relevant genes copies in the cancer cells

    05Rearrangements and fusions

    Structural variants whole-genome sequencing

    Chords join the two broken ends of each rearrangement over 1 Mb. The inner ring shows copy number.

    Fusion screen DNA breakpoints and RNA reads

    Treatment-relevant fusions, screened in both the genome and the RNA.

    Genes disrupted by a rearrangement

    06Genome-wide markers

    Tumour mutational burden mutations per Mb

    Microsatellite instability

    Homologous recombination

    Mutational signatures 96 trinucleotide contexts · liver biopsy

    The pattern of single-letter changes indicates the source of DNA damage. Each bar is one change in the context of its two neighbouring bases.

    07Clonal structure

    Clonal phylogeny

    Derived from the cancer-cell fractions of 41,590 mutations in the primary and the liver biopsy.

    Primary against liver cancer-cell fraction

    Each dot is a mutation. Mutations present in every cancer cell of both samples are at the top right.

    Synthetic results for the example patient. Somatic findings are reported by an accredited laboratory, and treatment decisions are made by the treating team.

    01Response over the treatment course

    Mutant molecules per mL of plasma (MM/mL), averaged across the panel, with tumour fraction on the right axis. CT dates are marked. Each point has a tooltip with the draw; selecting a point lists its variants below.

    MM/mLTumour fractionLimit of detection
    02Samples

    All blood draws with input and load. Selecting a row lists its variants below.

    03Rate of change on each therapy

    Fitted slopes log scale

    Response kinetics

    04Per-variant detail · MM/mL
    05Clone dynamics

    Share of tumour DNA from each clone. The PTEN subclone expanded during progression on immunotherapy from April to June and is now below detection.

    Truncal (A)PTEN subclone (B)RAC1 subclone (C)
    06Personalised panel · 24 variants

    Variants tracked in the blood selected from the tumour genome

    Panel design

    Synthetic results for the example patient. A rise in tumour DNA is interpreted with scans and clinical findings, not in isolation.

    01Image viewer
    CT abdomen and pelvis2 lesions outlined
    Open full screen
    Loading the viewer…
    ScrollslicesRight-dragbrightness and contrastCtrl+ScrollzoomNoutlines on or offGgo to the largest lesionDmeasure a length

    Images: a real, de-identified CT from a public collection in The Cancer Imaging Archive (Simpson et al., doi:10.7937/QXK2-QG03), CC BY 4.0, shown to illustrate the viewer; dates changed, sex and age removed. Outlines of the liver, its veins and the two lesions are the dataset's expert segmentation.

    02Scans in 2026
    03Target lesions

    Longest diameter mm · RECIST 1.1

    04Response over time

    Sum of target lesions mm

    01Summary
    02All results · 10 draws in 2026

    All blood results in 2026, grouped by system. H marks a result above the normal range, L below it. Each cell has a tooltip with the value and date; the i marker gives the interpretation of a change.

    Show
    03Trends by group
    04Interpretation of changes
      01Summary
      02Growth-rate waterfall · all 96 agents

      Dose-averaged growth-rate-normalised effect (GR) for every agent, ranked from least to most effect. Cytotoxic means cells were killed (GR below 0), growth inhibition means growth slowed, weak means little effect. Each bar has a tooltip with the drug and its target.

      CytotoxicGrowth inhibitionWeakCombination
      03Dose-response heatmap · viability at four doses

      Each number under C1–C4 and Mean is viability: the fraction of tumour cells still alive at that dose compared with untreated controls (1.00 = no effect, 0.20 = about 80% killed). C1 to C4 are 0.01, 0.1, 1 and 10 µM. Red is little effect, blue is cells killed. IC50 (greener = more potent) is the dose for half the maximal effect.

      Rank by
      Show
      Class
      04Dose-response curves

      Fitted curves with the three replicate measurements at each dose. Up to five agents can be displayed; the dashed line marks each IC50.

      05Combinations · synergy matrices

      Viability across a 6 × 6 dose grid.

      Synergy (Bliss excess)

      Excess kill of the pair over that expected if the two drugs acted independently. Above 10 is strong synergy.

      Combination
      06Response by drug class

      Each dot is one agent; the dark bar is the class median. Further left is more effect. Each dot has a tooltip with the drug.

      07Concordance with genomics

      Response predicted from the tumour DNA against response observed in the cells.

      08Assay quality

      Plate quality Z′ factor

      Above 0.5 is an excellent assay window.

      Replicate agreement viability, replicate 1 vs 2

      Controls

        Synthetic results for the example patient. Ex vivo responses support, and do not replace, clinical evidence; they are read alongside the genomics and the treating team's judgement.

        01Lesion burden over time

        All measured lesions on all CT scans, segmented in 3-D and compared on the same basis. Each point has a tooltip with its values; the measure, scale and comparator are selectable.

        Comparator
        02Individual lesion

        Segmentation · baseline CT expert outline

        CT slice with the lesion outlined

        Axial slice through the lesion on the baseline CT; orange is the lesion, beige the liver. Open in the viewer

        03Response assessment

        Spider plot % change in each lesion from baseline

        Best response by lesion volume, % from baseline

        Assessment at each scan RECIST 1.1 and volumetric

        04Scan comparability

        Volumes are directly comparable only when the scanner, slice thickness and contrast timing match. Amber marks an acquisition change that can alter a measurement independently of the disease.

        Baseline volumes are from the dataset's expert segmentation; follow-up measurements are synthetic for the example patient. Automated volumes support, and do not replace, the radiologist's report.

        01Summary
        02Gene viewer
        03Transcriptome explorer

        RNA sequencing of the 2 Jun 2026 liver biopsy. Each gene is ranked against 469 cutaneous melanomas (percentile) and compared with normal skin (log fold change). Genes can be filtered by family or searched by name. Selecting a gene opens it in the gene viewer above.

        Highpercentile ≥ 90 and log fold change ≥ 2Mediumpercentile ≥ 75 or |log fold change| ≥ 2Noteworthypercentile ≥ 60 or |log fold change| ≥ 1Lowbelow these, or reduced
        04Pathway activity

        Footprint scores from the expression of each pathway's target genes. Right is more active than other melanomas.

        05Tumour microenvironment

        Estimated cell mix from the expression profile.

        06Expression change after immunotherapy

        Primary 2025 → liver 2026 log2 change, selected genes

        Interpretation

          Synthetic results for the example patient. Expression is measured in bulk tissue, a mix of tumour and normal cells.

          01Today

          Doses today

          Selecting a dose marks it as taken.

          02Medication list
          03Treatment cycles · 28 days
          04Supply and refills
          05Adherence · last 7 weeks
          TakenHeld on adviceMissedClinic visit

          By medicine

          06Interactions and genes

          Interaction map tooltips on medicines and genes

          Moderate interactionMinorGene that metabolises or clears the medicine

          Interaction details

            Pharmacogenomics for current medicines Full results in Germline →

            07Medication timeline · 2026

            Synthetic medication record for the example patient. Interaction and pharmacogenomic checks support, and do not replace, review by a pharmacist.

            01Plan review · proposed liver SBRT

            Stereotactic radiotherapy plan for residual liver lesion 1, prepared for discussion at the multidisciplinary meeting if the response plateaus. No radiotherapy has been given before; no cumulative dose applies.

            02Dose distribution

            Isodose lines axial slice through the target

            CT slice with isodose lines

            Dose-volume histogram

            03Normal-tissue constraints
            04Biological dose

            Linear-quadratic model. BED = D × (1 + d / (α/β)); EQD2 = D × (d + α/β) / (2 + α/β). Outputs update with the values entered below.

            05Fraction schedule

            Synthetic plan for illustration, drawn on the baseline CT. Constraints are illustrative reference values for five-fraction liver SBRT, not a prescription.

            Demo: messages and files stay in this browser

            Synthetic conversation for the example patient. In a live dashboard, messages and files are stored in the patient's secure record, visible only to people the patient has invited, with every view and change logged.

            01Summary
            02Inherited cancer risk · 32-gene panel

            Whole-genome sequencing of blood, analysed across the genes linked to inherited melanoma and other cancers. Every gene was covered at 30× or more across all coding exons.

            No variant of concernVariant of uncertain significanceRisk modifierPathogenic

            Variants reported

            03Germline or somatic origin · tumour against blood

            Each tumour change was tested for in the blood. A change present in the tumour and absent from blood is somatic (acquired by the cancer), not inherited.

            04Family history
              05HLA type and secondary findings

              HLA class I used for neoantigen prediction

              Secondary findings ACMG SF v3.2, 81 genes

              06Pharmacogenomics · metabolism and tolerance of medicines

              Twelve genes that affect how medicines are broken down or tolerated. The marker shows the phenotype of the patient between poor and ultrarapid metabolism.

              Guidance by medicine CPIC and DPWG guidance

              Synthetic results for the example patient. Germline findings are confirmed by an accredited clinical genetics laboratory before they guide care, and genetic counselling is offered.

              01Summary
              02Lines of treatment
              03Current cycle · cycle 6, 28 days

              Both tablets are taken every day. Each square is one day; the dots are the doses. Each day has a tooltip with details.

              Encorafenib, morningBinimetinib, morning and eveningHeldToday
              04Dose levels
              05Response on each line

              Change from the start of each line, by week. The fall on line 2 is greater than on line 1 and is continuing.

              Line 1 · tumour DNALine 1 · lesionsLine 2 · tumour DNALine 2 · lesions
              06Side effects by month · CTCAE grade

              Highest grade in each month. Immune side effects occurred on line 1; skin, muscle and blood-pressure effects on line 2.

              1Mild2Moderate3Severe
              07Safety checks
              08Contingency options

              Synthetic treatment record for the example patient. Options are for discussion with the treating team; the tumour board decides.

              01Summary
              02Screening funnel

              All recruiting trials are checked against the record weekly. Each step excludes trials for which the record is ineligible.

              03Record data used for matching
              04Trials checked in detail · 9
              Sort
              05Criteria across all nine trials

              Each column is a trial, each row a fact from the record. Each mark has a tooltip with the exact criterion.

              ✓Met?Needs a test…Not yet✕Excludes
              06Factors that would change the matches

                The trials shown are invented examples for the synthetic patient. In a live dashboard the matcher searches the trial registers weekly; final eligibility is always decided by the trial team.

                01Today · 2 Nov, 08:10
                02Home readings · last 14 days
                03Fever episode · 29 October
                04Early-warning score · 29 Oct, 21:40

                NEWS2 adds points for each reading outside its normal band.

                05Symptom diary · last 8 weeks

                Reported each Sunday in the app, graded 0 to 3. Each cell has a tooltip with the note.

                06Escalation criteria
                07Devices and data

                Synthetic home readings for the example patient. Home monitoring supports, and does not replace, the treatment team's advice: in an emergency call 999.